Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J. Landovitz, Sheldon D. Fields, Leslie Cottle et al.|New England Journal of Medicine|2021Cited by 847
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J. Landovitz, Joseph J. Eron, Sue Li et al.|PLoS Medicine|2018Cited by 171